, Volume 116, Issue 2, pp 237–241

Effects of SR 48692, a selective non-peptide neurotensin receptor antagonist, on two dopamine-dependent behavioural responses in mice and rats


  • M. Poncelet
    • Neuropsychiatry DepartmentSanofi Recherche
  • J. Souilhac
    • Neuropsychiatry DepartmentSanofi Recherche
  • C. Gueudet
    • Neuropsychiatry DepartmentSanofi Recherche
  • J. P. Terranova
    • Neuropsychiatry DepartmentSanofi Recherche
  • D. Gully
    • Neuropsychiatry DepartmentSanofi Recherche
  • G. Le Fur
    • Neuropsychiatry DepartmentSanofi Recherche
  • P. Soubrié
    • Neuropsychiatry DepartmentSanofi Recherche

DOI: 10.1007/BF02245067

Cite this article as:
Poncelet, M., Souilhac, J., Gueudet, C. et al. Psychopharmacology (1994) 116: 237. doi:10.1007/BF02245067


One major mechanism underlying the central action of neurotensin is an interaction with the function of dopamine (DA)-containing neurons. In addition, direct or indirect DA agonists have been reported to promote neurotensin release. We have found that SR 48692, a non-peptide neurotensin receptor antagonist (0.04 – 0.64 mg/kg orally), antagonizes (50–65%) yawning induced by apomorphine (0.07 mg/kg SC) or bromocriptine (2 mg/kg IP) in rats, and turning behaviour induced by intrastriatal injection of apomorphine (0.25 µg), (+) SKF 38393 (0.1 µg), bromocriptine (0.01 ng) or (+) amphetamine (10 µg) in mice. Other apomorphine-induced effects in mice and rats such as climbing, hypothermia, hypo- and hyper-locomotion, penile erections and stereotypies were not significantly modified by SR 48692. Taken together, these data suggest that neurotensin may play a permissive role in the expression of some but not all behavioural responses to DA receptor stimulation.

Key words

SR 48692Neurotensin receptor antagonistDopamineApomorphineBromocriptine(+) SKF 38393(+) AmphetamineTurningYawningMouseRat

Copyright information

© Springer-Verlag 1994